《新股消息》第四範式境外上市備案材料獲中證監予以確認
人工智能企業第四範式就境外發行上市及境內未上市股份全流通已向中證監提交備案材料,並獲中證監予以確認,意味著距離可在港啟動首次公開發售(IPO)的時間愈來愈近。
據中證監公開資料顯示,第四範式計劃發行不超過9,085萬股境外上市普通股,並在香港聯交所上市,29名股東擬將所持合計約1.15億股境內未上市股份轉為境外上市股份,並在香港上市流通。
第四範式於今年5月再度提交上市申請,集資所得計劃用於加強基礎研究、提升技術能力、尋求戰略投資和收購,以及建立品牌等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.